Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions
Saurabhi Samant,Jules Joel Bakhos,Wei Wu,Shijia Zhao,Ghassan S Kassab,Behram Khan,Anastasios Panagopoulos,Janaki Makadia,Usama M Oguz,Akshat Banga,Muhammad Fayaz,William Glass,Claudio Chiastra,Francesco Burzotta,John F LaDisa Jr,Paul Iaizzo,Yoshinobu Murasato,Gabriele Dubini,Francesco Migliavacca,Timothy Mickley,Andrew Bicek,Jason Fontana,Nick E J West,Peter Mortier,Pamela J Boyers,Jeffrey P Gold,Daniel R Anderson,James E Tcheng,John R Windle,Habib Samady,Farouc A Jaffer,Nihar R Desai,Alexandra Lansky,Carlos Mena-Hurtado,Dawn Abbott,Emmanouil S Brilakis,Jens Flensted Lassen,Yves Louvard,Goran Stankovic,Patrick W Serruys,Eric Velazquez,Pierre Elias,Deepak L Bhatt,George Dangas,Yiannis S Chatzizisis
DOI: https://doi.org/10.1016/j.jcin.2023.07.022
2023-10-23
Abstract:Artificial intelligence, computational simulations, and extended reality, among other 21st century computational technologies, are changing the health care system. To collectively highlight the most recent advances and benefits of artificial intelligence, computational simulations, and extended reality in cardiovascular therapies, we coined the abbreviation AISER. The review particularly focuses on the following applications of AISER: 1) preprocedural planning and clinical decision making; 2) virtual clinical trials, and cardiovascular device research, development, and regulatory approval; and 3) education and training of interventional health care professionals and medical technology innovators. We also discuss the obstacles and constraints associated with the application of AISER technologies, as well as the proposed solutions. Interventional health care professionals, computer scientists, biomedical engineers, experts in bioinformatics and visualization, the device industry, ethics committees, and regulatory agencies are expected to streamline the use of AISER technologies in cardiovascular interventions and medicine in general.